DarolutamideMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3477070/fr/nubeqa-darolutamide-cancer-de-la-prostate-hormonosensible-metastatique-cphsm
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic combined chemotherapy protocols
Docetaxel
androgen receptor antagonists
Hormone-sensitive prostate cancer metastatic
neoplasm metastasis
Hormone sensitive prostate cancer (disorder)
adult
darolutamide
Darolutamide/Docetaxel Regimen
evaluation of the transparency committee
prostatic neoplasms
darolutamide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
darolutamide
darolutamide
darolutamide
prostatic neoplasms, Castration-Resistant
administration, oral
Product containing only darolutamide in oral dose form (medicinal product form)
androgen receptor antagonists
androgen receptor antagonists
product surveillance, postmarketing
adult
aged
drug interactions
survival analysis
drug evaluation, preclinical
pyrazoles
pyrazoles

---
https://www.has-sante.fr/jcms/p_3212149/fr/nubeqa
2020
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
darolutamide
darolutamide
prostatic neoplasms, Castration-Resistant
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
pyrazoles

---